IMRA News and Press, IMARA Inc. From 11/08/21

Preclinical data from three different mouse models of HFpEF to be presented at American Heart Association (AHA) Scientific Sessions HFpEF development to be led by cardiologist Toni Bransford, M.D., FACC, FASE Imara’s new Vice President of Clinical Development BO...

BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today an...

Tovinontrine (IMR-687) VOC data in patients with sickle cell disease from ongoing Phase 2a open-label extension study and preclinical models of beta-thalassemia to be presented Oral presentation provides first look at IMR-261, a novel oral Nrf2 activator shown to reactivate feta...

BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today a...

IMARA Inc. (IMRA) Q2 2021 Earnings Conference Call August 6, 2021 8:30 AM ET Company Participants Mike Gray – Chief Financial and Chief Operating Officer Rahul Ballal – President and Chief Executive Officer Ken Attie – Chief Medical Officer Conference Call Participants Co...

Accelerated enrollment in Phase 2b trials in sickle cell disease and beta-thalassemia; interim analyses expected in fourth quarter of 2021 Positive IMR-687 data in sickle cell disease presented at the European Hematology Association (EHA) Annual Congress HFpEF Phase 2 pr...

Imara (NASDAQ:IMRA) announces that the company has completed patient enrollment in the Ardent Phase 2b clinical trial of IMR-687, a potent small molecule inhibitor of PDE9, for the treatment of sickle cell disease (SCD). The company expects to report data from the primary analysis in the firs...

BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today an...

BOSTON, July 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company wi...

Gainers: AcelRx Pharmaceuticals ACRX +19%, GBS (GBS) +13%, Navidea Biopharmaceuticals (NAVB) +7%, Cellect Biotechnology (APOP) +6%, Adagene (ADAG) +2%.Losers: Allied Healthcare Products (AHPI) -34%, Allena Pharmaceuticals (ALNA) -31%, SCWorx (WORX)...